Disclosed herein is a composition comprising a biofilm degrading protease, a disulphide bond breaking agent and an antibiotic, as well as a method for debriding biofilm (e.g. on an implant) in a patient's body. The method comprises contacting the biofilm with a combination of a biofilm degrading protease and disulphide bond breaking agent.

Disclosed herein is a composition comprising a biofilm degrading protease, a disulphide bond breaking agent and an antibiotic, as well as a method for debriding biofilm (e.g. on an implant) in a patient's body. The method comprises contacting the biofilm with a combination of a biofilm degrading protease and disulphide bond breaking agent.

Disclosed herein is a composition comprising a biofilm degrading protease, a disulphide bond breaking agent and an antibiotic, as well as a method for debriding biofilm (e.g. on an implant) in a patient's body. The method comprises contacting the biofilm with a combination of a biofilm degrading protease and disulphide bond breaking agent.

The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).

The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).

Disclosed herein are methods for inducing production of full-length progranulin (GRN) from a nucleotide encoding a GRN with a premature stop codon (GRN-PTC), comprising exposing the GRN-PTC to an aminoglycoside. Methods for inducing production of full-length progranulin (GRN) from a nucleotide encoding a GRN with a premature stop codon (GRN-PTC), comprising administering gentamicin or G418 is also disclosed.

Disclosed herein are methods for inducing production of full-length progranulin (GRN) from a nucleotide encoding a GRN with a premature stop codon (GRN-PTC), comprising exposing the GRN-PTC to an aminoglycoside. Methods for inducing production of full-length progranulin (GRN) from a nucleotide encoding a GRN with a premature stop codon (GRN-PTC), comprising administering gentamicin or G418 is also disclosed.

Provided herein is a topical antibiotic composition that includes an external antibiotic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical antibiotic composition.

Provided herein is a topical antibiotic composition that includes an external antibiotic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical antibiotic composition.

The invention relates to methods, kits and compositions for reducing the level of or eliminating Bacteroides in situ. The invention encompasses methods of preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof, comprising reducing the amount of Bacteroides sp. in the subject. The invention further encompasses methods of diagnosis of a subject as having myocarditis or dilated cardiomyopathy. The invention also encompasses compositions preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof.